The United States Food and Drug Administration has approved Cephalon's Treanda® (bendamustine hydrochloride) for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of therapy with Rituxan® (rituximab) or Rituxan-containing regimens.
This is the second approval for Treanda this year; the drug is also approved for the treatment of chronic lymphocytic leukemia.
Treanda is a synthesized agent that contains both an alkylating group and a purine-like benzimidazole component. Treanda is thought to provide its anticancer activity through apoptosis and mitotic catastrophe.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
